Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.58 |
| ▸ | PGR | P06401 | 18/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942959 | 1.00 | AR (0.58) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL13556643 | 1.00 | AR (0.58) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL12998939 | 0.91 | AR (0.47) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL12942946 | 0.88 | AR (0.45) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL13768837 | 0.88 | AR (0.49) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL12942739 | 0.86 | AR (0.57) | ARPGRNR3C2 | |
| SCHEMBL12942849 | 0.86 | AR (0.57) | ARPGRNR3C2 | |
| SCHEMBL12942781 | 0.86 | AR (0.57) | ARPGRNR3C2 | |
| SCHEMBL12998952 | 0.85 | AR (0.64) | ARPGRNR3C2LMNAABCC4 | |
| SCHEMBL16572779 | 0.85 | AR (0.64) | ARPGRNR3C2LMNAABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445469-B2 | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445469-B2 | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-1831240-B1 | 18-METHYL-19-NOR-17-PREGN-4-EN-21,17-CARBOLACTONES AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | SCHERING AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20090029953-A1 | 18-METHYL-19-NOR-17-PREGN-4-ENE-21,17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER | BAYER SCHERING PHARMA AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029953-A1 | 18-METHYL-19-NOR-17-PREGN-4-ENE-21,17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER | BAYER SCHERING PHARMA AG (DE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029953-A1 | 18-METHYL-19-NOR-17-PREGN-4-ENE-21,17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER | HSD17B7, HSD17B11, HSD3B1 | AR 100/4885PGR 24/4885NR3C2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.